Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Ipatasertib|DRUG: Trastuzumab|DRUG: Pertuzumab
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Roche Pharma AG